Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Dr-reddy
REZAK (capsules) SCHEDULING STATUS: S5 PROPRIETARY NAME (and dosage form): REZAK (capsules) COMPOSITION Each capsule contains fluoxetine hydrochloride equivalent to 20 mg fluoxetine PHARMACOLOGICAL CLASSIFICATION A 1.2 Psychoanaleptics (antidepressants) PHARMACOLOGICAL ACTION Pharmacodynamics The antidepressant and anti-obsessive-compulsive action of fluoxetine is presumed to be linked to its inhibition of central nervous system (CNS) neuronal uptake of serotonin. Studies at clinically relevant doses in man have demonstrated that fluoxetine blocks the uptake of serotonin into human platelets. Pharmacokinetics Because of the long elimination half-life of the parent drug (4 to 6 days) and its major active metabolite norfluoxetine (4 to 16 days), changes in dose will not be fully reflected in plasma for several weeks (approximately 4 half-lives). This is to be taken into consideration during dose titration or cessation of treatment. INDICATIONS Major depressive episodes i.e. single episode and recurrent depression with associated anxiety. Bulimia nervosa REZAK has been shown to significantly decrease binge-eating and purging activity. Obsessive-compulsive disorder REZAK is indicated for the treatment of obsessive-compulsive disorder. The obsessions or compulsions must be experienced as intrusive, markedly distressing, time consuming or interfering significantly with the person’s social or occupational functioning. CONTRAINDICATIONS Hypersensitivity to fluoxetine. REZAK should not be administered to patients with severe renal failure (GFR < 10 mL/min) because accumulation may occur in these patients during chronic treatment. Monoamine oxidase inhibitors There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with p Read the complete document